The FDA Wants to be Attacked Again

     As a guardian of the two companies that my blog defends, I am on the lookout for any political aggressor that seeks to throttle AbbVie Inc. (ABBV) and/or Eli Lilly & Co. (LLY).  Yesterday, an attack came once again from the FDA, this time directed at AbbVie (ABBV).

Government regulators force medical companies to do extensive clinical tests before they will withdraw their ban on new medical products.  These tests are based on statistics which enshrine collectivism in their methodology.  But, the genes of individuals are not the same.  Therefore, individual responses to pharmaceutical drugs and other medicines often differ, as well.

For example, consider the field of mood disorder treatment.  What would happen if the FDA required that a pharmaceutical company clinically test a new mood drug among 2,000 patients?  Considering that there is a common disposition among many individuals to have levels of: mania, depression, or manic-depression at different times, as genetically driven manifestations, what would the test mean?  Nothing.

With the dawn of advanced biotechnology that enables medical scientists to identify the genes of an individual and their expression, the FDA really needs to get out of the way and stop preventing each individual American from having access to being able to purchase medical products and services that facilitate one's optimal health.

Paul Wharton
Special thanks to Eli Lilly & Co. (LLY)